95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Agustini Utari1,2*
Sultana M. H. Faradz1
Annastasia Ediati1,3
Tuula Rinne4
Mahayu Dewi Ariani1
Achmad Zulfa Juniarto1Stenvert L. S. Drop5
Antonius E. van Herwaarden6
Hedi L. Claahsen-van der Grinten7- 1Center for Biomedical Research (CEBIOR), Faculty of Medicine, Diponegoro University, Semarang, Indonesia
- 2Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Diponegoro University, Semarang, Indonesia
- 3Faculty of Psychology, Diponegoro University, Semarang, Indonesia
- 4Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands
- 5Division of Pediatric Endocrinology, Sophia Children’s Hospital and Erasmus Medical Center, Rotterdam, Netherlands
- 6Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands
- 7Division of Pediatric Endocrinology, Department of Pediatrics, Amalia Children’s Hospital, Radboud University Medical Center, Nijmegen, Netherlands
by Utari A, Faradz SMH, Ediati A, Rinne T, Ariani MD, Juniarto AZ, Drop SLS, van Herwaarden AE and Claahsen-van der Grinten HL (2022) Front. Endocrinol. 13:1015973. doi: 10.3389/fendo.2022.1015973
In the published article, there was an error in the Acknowledgments statement. The following sentence was missing from the statement and has now been added.
“The presented work resulted from collaboration made possible through the ESPE sponsored programme “ESPE Visiting Professorship” supported by Pfizer.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: congenital adrenal hyperplasia, CYP11B1 deficiency, differences (disorders) of sex development, developing country, guideline
Citation: Utari A, Faradz SMH, Ediati A, Rinne T, Ariani MD, Juniarto AZ, Drop SLS, van Herwaarden AE and Claahsen-van der Grinten HL (2023) Corrigendum: Challenges in the treatment of late-identified untreated congenital adrenal hyperplasia due to CYP11B1 deficiency: Lessons from a developing country. Front. Endocrinol. 14:1210892. doi: 10.3389/fendo.2023.1210892
Received: 23 April 2023; Accepted: 25 April 2023;
Published: 04 May 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Utari, Faradz, Ediati, Rinne, Ariani, Juniarto, Drop, van Herwaarden and Claahsen-van der Grinten. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Agustini Utari, YWd1c3Rpbml1dGFyaUBnbWFpbC5jb20=